Healthcare company Adcock Ingram Holdings confirmed it had withdrawn its dextro propoxyphene (DPP)-containing medicines from the South African market, Fin24 reports.
The US Food and Drug Administration withdrew DPP from the US market on November 19, after determining that the benefits of DPP for pain relief at US-recommended doses outweighed the safety risk.
The regulator requested that suppliers voluntarily withdraw any drugs containing DPP from the US market.
According to media reports, new research showed the drug was linked to serious abnormal heart rhythms.
DPP is a compound with pain-relieving properties found in three of Adcock Ingram's drugs - Synap Forte, Lentogesic and Doxyfene, the group said.
Just R20 for the first month. Support independent journalism by subscribing to our digital news package.